A novel approach to detect cumulative genetic effects and genetic interactions in Crohn's disease

Inflammatory Bowel Diseases

Volumn 19, Issue 9, 2013, Pages 1799-1808

  Wang, Ming Hsi ^a   Fiocchi, Claudio ^a   Ripke, Stephan ^b   Zhu, Xiaofeng ^c   Duerr, Richard H ^d,e   Achkar, Jean Paul ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Crohn's disease; Cumulative genetic effect; Genetic interaction; Genetics

Indexed keywords

ALLELE; ARTICLE; ATG16L1 GENE; C13ORF31 GENE; CHROMOSOME 21Q; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; GENE; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HERITABILITY; HUMAN; IL10 GENE; NOD2 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; CASE-CONTROL STUDIES; CROHN DISEASE; EPISTASIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PROGNOSIS; QUANTITATIVE TRAIT LOCI; RISK FACTORS;

EID: 84884598280     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e31828706a0     Document Type: Article

References (41)

1. Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
2. Liu S, Song Y. Building genetic scores to predict risk of complex diseases in humans: is it possible? Diabetes. 2010;59:2729-2731.
3. Yang Q, Khoury MJ, Botto L, et al. Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes. Am J Hum Genet. 2003;72:636-649.
4. Wray NR, Goddard ME, Visscher PM. Prediction of individual genetic risk to disease from genome-wide association studies. Genome Res. 2007; 17:1520-1528.
5. Weersma RK, Stokkers PCF, Cleynen I, et al. Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol. 2009;104:630-638.
6. Peter I, Mitchell A, Ozelius L, et al. Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet. 2011;12:63.
7. Park JH, Gail MH, Weinberg CR, et al. Distribution of allele frequencies and effect sizes and their interrelationships for common genetic susceptibility variants. Proc Natl Acad Sci USA. 2011;108:18026-18031.
8. Zuk O, Hechter E, Sunyaev SR, et al. The mystery of missing heritability: genetic interactions create phantom heritability. Proc Natl Acad Sci USA. 2012;109:1193-1198.
9. Ruczinski I, Kooperberg C, LeBlanc L. Logic regression. J Comput Graph Stat. 2003;12:475-511.
10. Ruczinski I, Kooperberg C, LeBlanc L. Exploring interactions in highdimensional genomic data: an overview of logic regression, with applications. J Mult Anal. 2004;90:178-195.
11. Schwender H, Ruczinski I. Logic regression and its extensions. Adv Genet. 2010;72:25-45.
12. Achkar JP, Klei L, Bakker PIW, et al. Amino acid position 11 of HLA-DR [beta]1 is a major determinant of chromosome 6p association with ulcerative colitis. Genes Immun. 2012;13:245-252.
13. Browning BL, Browning SR. A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. 2009;84:210-223.
14. Marchini J, Howie B, Myers S, et al. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet. 2007;39:906-913.
15. The Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661-678.
16. Li Y, Willer C, Sanna S, et al. Genotype imputation. Annu Rev Genomics Hum Genet. 2009;10:387-406.
17. Li Y, Willer CJ, Ding J, et al. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol. 2010; 34:816-834.
18. Makowsky R, Pajewski NM, Klimentidis YC, et al. Beyond missing heritability: prediction of complex traits. PLoS Genet. 2011;7:e1002051.
19. Stokes ME, Davis C, Koch G. Categorical Data Analysis Using the SAS System. Second Edition. Cary, NC: SAS Institute Inc.; 2000.
20. Breiman L, Friedman JH, Stone C, et al. Classification and Regression Trees. Monterey, CA: Wadsworth & Brooks; 1984.
21. Friedman JH, Roosen CB. An introduction to multivariate adaptive regression splines. Stat Methods Med Res. 1995;4:197-217.
22. Berzuini C, Dawid P, Zhang H, et al. Analysis of interaction for identifying causal mechanisms. In: Berzuini C, Dawid P, Bernardinelli L, eds. Causality: Statistical Perspectives and Applications. Wiley; 2012: 192-207.
23. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
24. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411: 603-606.
25. Homer CR, Richmond AL, Rebert NA, et al. ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in Crohn's disease pathogenesis. Gastroenterology. 2010;139: 1630-1641.
26. Travassos LH, Carneiro LAM, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010;11:55-62.
27. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol. 2004;10:620-625.
28. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 1993;75:263-274.
29. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology. 2012;143:347-355.
30. Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361: 2033-2045.
31. Netea MG, Kullberg BJ, de Jong DJ, et al. NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol. 2004;34:2052-2059.
32. Noguchi E, Homma Y, Kang X, et al. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nat Immunol. 2009;10:471-479.
33. Azuma YT, Matsuo Y, Kuwamura M, et al. Interleukin-19 protects mice from innate-mediated colonic inflammation. Inflamm Bowel Dis. 2010;16: 1017-1028.
34. Valero R, Marfany G, Gonzalez-Angulo O, et al. USP25, a novel gene encoding a deubiquitinating enzyme, is located in the gene-poor region 21q11.2. Genomics. 1999;62:395-405.
35. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature. 2003;424:801-805.
36. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451-452.
37. Graner E, Tang D, Rossi S, et al. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004;5: 253-261.
38. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med. 2009;361:2609-2618.
39. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008;40:955-962.
40. Keri RA, Ho SM, Hunt PA, et al. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol. 2007;24: 240-252.
41. Cho JH, IIBDGC. Immunochip-based analysis of a large IBD case-control cohort identifies 50 novel loci, refining definitions of disease pathways. Gastroenterology. 2012;142:S149-S150.